A senior House Democrat is pressing the White House to say plainly whether President Donald Trump quietly secured an experimental obesity drug that the government reserves for the gravely ill.
Representative Ted Lieu of California raised the question at a Capitol press conference on Wednesday, hours after Trump abruptly scrapped a housing bill signing. His challenge was built on a STAT exclusive reporting that a single 79-year-old man had been granted early access to Eli Lilly's retatrutide through a programme normally tied to terminal illness.
